ATG2B and breast cancer: Regarding the MDA-MB-231 cells, in agreement with our BC signature, overexpression of BECN1 or ATG2B decreased cell proliferation whereas inhibition of ATG5, but not LC3B, also reduced cell proliferation in this TNBC cell model (Figure 4D-4E).